About The Study: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of the antibiotic meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28.
Authors: Giovanni Landoni, M.D., of the IRCCS San Raffaele Scientific Institute in Milan, Italy, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.10598)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the 2023 Critical Care Reviews meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.10598?guestAccessKey=b0f75c6d-25ba-4e55-8106-531c0288a645&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061623
JAMA